Single-nucleus transcriptome analysis reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in Alzheimer’s disease
Alzheimer’s disease (AD) is the most common form of dementia but has no effective treatment. A comprehensive investigation of cell type-specific responses and cellular heterogeneity in AD is required to provide precise molecular and cellular targets for therapeutic development. Accordingly, we perfo...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 117; no. 41; pp. 25800 - 25809 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
13.10.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Alzheimer’s disease (AD) is the most common form of dementia but has no effective treatment. A comprehensive investigation of cell type-specific responses and cellular heterogeneity in AD is required to provide precise molecular and cellular targets for therapeutic development. Accordingly, we perform single-nucleus transcriptome analysis of 169,496 nuclei from the prefrontal cortical samples of AD patients and normal control (NC) subjects. Differential analysis shows that the cell type-specific transcriptomic changes in AD are associated with the disruption of biological processes including angiogenesis, immune activation, synaptic signaling, and myelination. Subcluster analysis reveals that compared to NC brains, AD brains contain fewer neuroprotective astrocytes and oligodendrocytes. Importantly, our findings show that a subpopulation of angiogenic endothelial cells is induced in the brain in patients with AD. These angiogenic endothelial cells exhibit increased expression of angiogenic growth factors and their receptors (i.e., EGFL7, FLT1, and VWF) and antigen-presentation machinery (i.e., B2M and HLA-E). This suggests that these endothelial cells contribute to angiogenesis and immune response in AD pathogenesis. Thus, our comprehensive molecular profiling of brain samples from patients with AD reveals previously unknown molecular changes as well as cellular targets that potentially underlie the functional dysregulation of endothelial cells, astrocytes, and oligodendrocytes in AD, providing important insights for therapeutic development. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Reviewers: M.E.E., Icahn School of Medicine at Mount Sinai; W.M., University of California, San Diego; and H.S., University of Pennsylvania. Author contributions: S.-F.L., A.K.Y.F., and N.Y.I. designed research; S.-F.L. performed research; S.-F.L. and N.Y.I. contributed new reagents/analytic tools; S.-F.L., H.C., A.K.Y.F., and N.Y.I. analyzed data; and S.-F.L., A.K.Y.F., and N.Y.I. wrote the paper. Contributed by Nancy Y. Ip, September 3, 2020 (sent for review May 5, 2020; reviewed by Michelle E. Ehrlich, William Mobley, and Hongjun Song) |
ISSN: | 0027-8424 1091-6490 1091-6490 |
DOI: | 10.1073/pnas.2008762117 |